Audited by the world's most stringent regulatory entities, its two production facilities located in Argentina and Brazil enable us to offer a portfolio of options for animal health that meet the highest quality standards.

With a portfolio of well-known brands and more than 80 years of experience, it is the #1 pharmaceutical company in Argentina in terms of sales. Its products are backed by international quality and safety standards. It stands out in women's health with products for each stage of women's lives. One of its most recent achievements has been the development of the first estrogen-free oral contraceptive, a new option that broadens access of women to effective and safe solutions.

It developed the world's first biological with potential to avoid progression of the hemolytic-uremic syndrome. Additionally, during the pandemic, it created horse-derived hyperimmune plasma to treat moderate to severe COVID-19.

During the COVID-19 crisis, it deployed technology in record time to produce the active pharmaceutical ingredient (API) for the Oxford-AstraZeneca vaccine.

It is the regional office of Insud Pharma and the liaison between Grupo Insud and its other companies in the pharma business.

It has strategic partnerships with Novartis, Pfizer, Merck Sharp & Dohme and mAbxience. With its open innovation approach, it ensures the supply of vaccines to meet national demand and for export to other countries in the region. Its facility produces the flu vaccine, the conjugate pneumococcal vaccine and the quadrivalent vaccine against the Human Papillomavirus (HPV). Its annual production capacity reaches 50 million doses.